DiagNodus has developed innovative technologies focused on the non-invasive diagnosis and monitoring of colorectal diseases, particularly inflammatory bowel disease (IBD) and colorectal cancer (CRC). Their patented methods facilitate the collection and analysis of biological samples that indicate the state of the human bowel, utilizing disease biomarker detection. This approach not only enhances the accuracy of diagnostics but also aims to improve patient experience by providing a more convenient alternative to traditional screening methods, such as the faecal occult blood test (FOBT). The company has established analytical laboratory techniques for quantitative immunochemical determination of IBD markers and is in the process of creating disposable, single-use point-of-care test kits for rapid testing.

The technology developed by DiagNodus is designed to be inexpensive, non-invasive, and user-friendly, allowing for self-application by patients. It promises to deliver results with greater sensitivity and specificity than existing methods, thereby addressing the limitations of current screening practices. By enabling the non-invasive determination of bowel inflammation activity, DiagNodus's approach not only facilitates effective diagnosis and monitoring of IBD but also represents a potential paradigm shift in CRC screening, ultimately aiming to enhance patient compliance and outcomes in colorectal health management.

United Kingdom

DiagNodus is a biomedical research services company that specializes in pathology and molecular biology, offering laboratory-based projects, research design, clinical trial services, and sample analysis.

DiagNodus

Company Details